Stability Indicating Isocratic RP-HPLC Method for Simultaneous Estimation of Nivolumab and Relatlimab in Bulk and Pharmaceutical formulation
Authors
Department of Pharmaceutical Analysis, NRI College of Pharmacy, Pothavarappadu (V), Agiripalli (M), Eluru (Dt) Andhra Pradesh (India)
Department of Pharmaceutical Analysis, NRI College of Pharmacy, Pothavarappadu (V), Agiripalli (M), Eluru (Dt) Andhra Pradesh (India)
Department of Pharmaceutical Analysis, NRI College of Pharmacy, Pothavarappadu (V), Agiripalli (M), Eluru (Dt) Andhra Pradesh (India)
Department of Pharmaceutical Analysis, NRI College of Pharmacy, Pothavarappadu (V), Agiripalli (M), Eluru (Dt) Andhra Pradesh (India)
Department of Pharmaceutical Analysis, NRI College of Pharmacy, Pothavarappadu (V), Agiripalli (M), Eluru (Dt) Andhra Pradesh (India)
Department of Pharmaceutical Analysis, NRI College of Pharmacy, Pothavarappadu (V), Agiripalli (M), Eluru (Dt) Andhra Pradesh (India)
Article Information
DOI: 10.51244/IJRSI.2025.12110162
Subject Category: Social science
Volume/Issue: 12/11 | Page No: 1846-1861
Publication Timeline
Submitted: 2025-12-03
Accepted: 2025-12-10
Published: 2025-12-22
Abstract
A simple, rapid, precise, sensitive and reproducible reverse phase high performance liquid chromatography (RP-HPLC) method has been developed for the quantitative analysis of Nivolumab and Relatlimab in bulk and pharmaceutical dosage form. Chromatographic separation of Nivolumab and Relatlimab was achieved on Waters Alliance-e2695 by using Phenyl (250x 4.6mm, 5µ) column and the mobile phase containing Acetonitrile: TEA pH-2.5/OPA in the ratio of 50:50% v/v. The flow rate was 1.0 ml/min; detection was carried out by absorption at 222nm using a photodiode array detector at ambient temperature. The number of theoretical plates and tailing factor for Nivolumab and Relatlimab were NLT 2000 and should not more than 2 respectively. % Relative standard deviation of peak areas of all measurements always less than 2.0. The proposed method was validated according to ICH guidelines. The method was found to be simple, economical, suitable, precise, accurate & robust method for quantitative analysis of Nivolumab and Relatlimab.
Keywords
Nivolumab, Relatlimab, RP-HPLC, Isocratic
Downloads
References
1. Pardoll DM (March 2012). "The blockade of immune checkpoints in cancer immunotherapy". Nature Reviews. Cancer. 12 (4): 252–64. doi:10.1038/nrc3239. [Google Scholar] [Crossref]
2. Syn NL, Teng MW, Mok TS, Soo RA (December 2017). "De-novo and acquired resistance to immune checkpoint targeting". The Lancet. Oncology. 18 (12): e731–e741. doi:10.1016/s1470-2045(17)30607-1 [Google Scholar] [Crossref]
3. Maruhashi T, Sugiura D, Okazaki IM, Okazaki T: LAG-3: from molecular functions to clinical applications. J Immunother Cancer. 2020 Sep;8(2). [Google Scholar] [Crossref]
4. "Opdivo- nivolumab injection". DailyMed. 17 December 2019. Retrieved 11 March 2020. [Google Scholar] [Crossref]
5. European Medicines Agency (EMA). 30 January 2020. Retrieved 11 March 2020. [Google Scholar] [Crossref]
6. "Nivolumab (Opdivo) Use During Pregnancy". Drugs.com. 4 November 2019. [Google Scholar] [Crossref]
7. Cavagnaro JA, Cosenza ME, eds. (2021). Translational Medicine: Optimizing Preclinical Safety Evaluation of Biopharmaceuticals. Boca Raton, Florida: CRC Press. [Google Scholar] [Crossref]
8. Robert C (December 2021). "LAG-3 and PD-1 blockade raises the bar for melanoma". Nature Cancer. 2 (12): 1251–3. [Google Scholar] [Crossref]
9. Pardoll DM (March 2012). "The blockade of immune checkpoints in cancer immunotherapy". Nature Reviews. Cancer. 12 (4): 252–64. doi:10.1038/nrc3239 [Google Scholar] [Crossref]
10. Syn NL, Teng MW, Mok TS, Soo RA (December 2017). "De-novo and acquired resistance to immune checkpoint targeting". The Lancet. Oncology. 18 (12): e731–e741. doi:10.1016/s1470-2045(17)30607-1 [Google Scholar] [Crossref]
11. Caponnetto S, Draghi A, Borch TH, Nuti M, Cortesi E, Svane IM, Donia M (May 2018). "Cancer immunotherapy in patients with brain metastases". Cancer Immunology, Immunotherapy. 67 (5): 703–711. [Google Scholar] [Crossref]
12. Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. (November 2019). "Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer". The New England Journal of Medicine. 381 (21): 2020–2031. [Google Scholar] [Crossref]
Metrics
Views & Downloads
Similar Articles
- The Impact of Ownership Structure on Dividend Payout Policy of Listed Plantation Companies in Sri Lanka
- Urban Sustainability in North-East India: A Study through the lens of NER-SDG index
- Performance Assessment of Predictive Forecasting Techniques for Enhancing Hospital Supply Chain Efficiency in Healthcare Logistics
- The Fractured Self in Julian Barnes' Postmodern Fiction: Identity Crisis and Deflation in Metroland and the Sense of an Ending
- Impact of Flood on the Employment, Labour Productivity and Migration of Agricultural Labour in North Bihar